StockWatch
·

KOPRAN LTD.

BSE: 524280

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
87.98
+34.0%+106.0%
Expenditure
79.57
+39.9%+67.2%
Net Profit
6.29
-6.5%+257.4%
OPM %
11.85%
-1.62pp+19.41pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-18.7619.3857.5295.67133.81Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Kopran turns profitable YoY in Q2 FY27 — consol PAT ₹4.4 Cr vs loss; revenue up 79%

pharmaceuticals · api · profit turnaround

ResultsQ2 FY2703 Nov 20263 minPharma & Healthcare

Kopran Q1 FY27: consolidated PAT -10% YoY as subsidiaries swing to loss; standalone +91%

pharmaceuticals · api manufacturing · margin compression

ResultsQ1 FY2707 Aug 20263 minPharma & Healthcare
Latest
Quarterly Result3 Nov, 1:38 pm

Kopran turns profitable YoY in Q2 FY27 — consol PAT ₹4.4 Cr vs loss; revenue up 79%

Kopran's consolidated Q2 FY27 (quarter ended September 30, 2026) print is a clean year-on-year turnaround: PAT of ₹4.39 Cr against a ₹9.92 Cr loss in Q2 FY26, on revenue up 79.2% YoY to ₹211.26 Cr. Neither period carries exceptional items, so the swing is operating, not one-off driven. Sequentially, though, the quarter cooled off — PAT fell 34.4% from ₹6.70 Cr in Q1 FY27 even as revenue kept climbing 37.2% QoQ, and OPM slipped to ~7.3% from 10.3% in Q1 FY27 (still well above the -4.5% a year ago), with NPM easing to 2.1% from 4.3% QoQ. Standalone tells a better bottom-line story — PAT of ₹6.29 Cr (EPS ₹1.30) versus the group's ₹4.39 Cr (EPS ₹0.91) — a gap the auditor's limited review traces to roughly a ₹2.1 Cr quarterly net loss at one overseas subsidiary; readers comparing the two numbers should note this is why they diverge rather than assume an error. There is no prior guidance or concall commentary on record for Kopran, and a web search turned up no analyst or consensus estimates for this quarter either — both the guidance and street checks resolve to unknown for lack of coverage on this smallcap. The margin give-back sits mainly in the cost lines rather than other income: finance costs and depreciation both grew faster than other income on a rising capex and borrowings base, consistent with the company scaling up even as near-term profitability gave back part of Q1's gain. The quarter's one concrete regulatory datapoint — the EU GMP inspection at the Khopoli facility concluding successfully on October 22, 2026 — is a relevant quality-compliance signal alongside this quarter's growth, though the filing reports a single pharmaceuticals segment under Ind AS 108 with no revenue break-up to size its contribution. No management press release was available to cross-check against the reported numbers.

3 Nov 2026, 01:38 pm

Corporate Events

Board MeetingKOPRAN
2026
3Nov

Board Meeting

The Board Meeting is scheduled to consider and approve Unaud…

BSE Filing ↗
Board MeetingKOPRAN
2026
18Aug

Board Meeting

The Annual General Meeting of the Company is scheduled to be…

BSE Filing ↗
Board MeetingKOPRAN
2026
7Aug

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingKOPRAN
2024
13Nov

Board Meeting

Meeting of the Board of Directors of the Company is schedule…

BSE Filing ↗
DividendKOPRAN
2024
11Sep

₹3 / share

BSE Filing ↗
Board MeetingKOPRAN
2024
7Feb

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗
Board MeetingKOPRAN
2023
7Nov

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗
Board MeetingKOPRAN
2023
10Aug

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗